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Tms paper is concerned withtheproblem ofwhetherthe incidence ofmalignant
diseases in diabetics is significantly different from that in non-diabetics. While
the material of autopsies from the Pathology Department of Bristol Universitv
and the chnical material from the Bristol Royal Infirmarv confirm the negative
association between the two diseases which has been the subject of previous
investigations, a critical examination reveals the new fact that such a negative
association would seem toapplv more to females. It is shown that theexplanation
of a negative association between mahgnant tumours and diabetes is in agreement
with what has emerged so far about a hormonal impfication via the disturbance
of the glucose metabohsm in both diseases.
The results of an examination ofpost mortem records in thePatholog-N-Depart-
ment of the Universitv of Bristol are shown in Table 1.
TABLEI.-Mortality Due toJlalignant Tumours andDiabetesfrain th-e Post
Mortein Reeords in thR Pathology Department. t'niversity of Bristol
Total number of post-mortem records in the Bristol Patholop- Department 6317
Xiimber ofmalignant tiimours among them 1212
Xiimber of diabetics among the 6317 records 189
_Niimber of coiLneidences of diabet-es and cancer 19
Percentage ofmalignant cases 'm the total of 6317 cases 19-2
Percentage ofmalignant tumours among non-diabetics (I193 6128) 19-5
Pereentage ofmalignant tumours among diabetics 10-1
Table 11 gives the clistribution ofpost mortems (P.M.'s) according to age and
sex for the total of P.M.'s. the cases of malignant tumours, ofdiabetes, and the
cases ofjoint occurrence ofmalignant tumour and diabetes.
Particular attention is drawn to the fact that the age distribution (total) of
diabetics appears to be, by andlarge, agood replica ofthat for diabetes morbiditv
in the general population. It shows the characteristic increase in diabetes mor-
biditv between the ages 50-80 with a pronounced peak between 60 and 70 just
hk-e ihe diabetes morbiditv curve in the general population.
On the face of it the diabetics appear. according to Table 1. less susceptible
to the malignant disease, the difference being about 9 per cent. There is nothing in the age distributions as displaved in Table H which would suggest a statistical
bias to be responsible for that difference. Since we are deahng here only with
samples-although fairlv lar-ae ones-a difference of this type is to be tested for
significance. The significance test can be carried out in different wavs. We450 G. HERDAN
TABLE II.-Age and Sex Distribution of the Post Mortem Cases
Summarized in Table I
Cases of Malignant
Total of malignant Cases of tumour plus
P.M.'s tumours diabetes diabetes
Age .11, 'k t A r A -N
group M. F. Total M. F. Total M. F. Total M. F. Total
0-9 840 657 1497 19 18 32 2 3 5
10-19 99 97 196 7 8 15 0 1 1
20-29 149 151 300 14 7 21 2 3 5
30-39 186 185 371 23 18 41 2 5 7
40-49 367 281 648 75 49 124 9 8 17 1 2 3
50-59 637 369 1006 166 114 280 12 24 36 3 1 4
60-69 717 450 1167 224 119 243 17 45 62 2 3 5
70-79 503 351 854 176 96 275 13 32 45 4 2 6
80-89 133 120 253 47 28 75 4 7 11 I 1
90-99 10 14 24 2 2 4
100 + I 1
Totals 3641 2676 6317 753 459 1212 61 128 189 11 8 19
may first regard the percentage ofmalignant tumours among the total of autop-
sies-6317-as the statistical population percentage ofmalignant disease, and the
number of diabetics-189-as a random sample of the total. We then have,
for the standard error of the population percentage in such a sample of 1819
specimens
19-2 x 80-8 2-86% 189
and 3o- 8-56 per cent added and subtracted from the basic percentage, 19-2,
gives 27-76 per cent and 10-64 per cent respectively as the upper and lower limits
within which we could expect the percentage ofmalignant tumours in a sample of
189 specimens to lie. The observed percentage of 10-1 among the 189 diabetics
liesbeyond the 3o- limit and is, therefore, to beregarded ashighlysignificant of an
assignable cause.
The same answer is obtained if we estimate the population percentage on the
basis of the sample percentage, by means of the chart on page 61 of
' Statistics of
Therapeutic Trials' (Herdan, 1955). Entering the chart with p 10-1 on the
upper horizontal scale and projecting the crossing point of the vertical with the
curve n 189 to the left (or right), we read there the difference between the
upper limit for the population probability p., and p as slightly less than 8, and
obtain, therefore, the upper limit p. as slightly less than 18, which is significantly
smaller than the observed figure, 19-1 per cent.
A second possibility is to regard both the percentage of malignant tumours
among the total of P.M.'s and that of coincidence cases of the two diseases as
samples from the statistical population of P.M.'s in the wi-der sense, say in the
whole ofthe country, and determine the significance between the two. The result
is essentially as before.
Section 2
It is now important that there is a remarkable stability ofthe figures obtained
for the malignant disease, in general, and among diabetics, not only within a
country, but between countries, and significance tests could also be carried outCANCER AND DIABETES MELLITUS
on the percentages of the same description but in different countries. That is,
we could compare the percentages of malignant diseases in, say, England and
Germany, and the percentage of coincidence cases in these two countries.
The justification for such a procedure-which is rather important both from
the theoretical and practical angle as will be explained below, can be seen from
Table III which gives relevant numbers as in Table I for six investigations of
that kind.
TABLE III.-Mortality Due to Malignant Tumours and Diabetes from
German Post Mortem Records
Rockstroh
and
Kruger Mallory Eskuchen Welsch Eiehler Werner Schroter
(1940) In. (1947) (1952) (1954) (1953) (1960)
Post mortems . . 5,844 - 10,948 13,546 19,242 25,147 22,971
Malignant tumours . 731 1,894 2,271 3,524 4,989 4,142
Diabetics . 122 307 236 402 637 705 351
Malignant tumours and diabetics . 10 24 21 40 59 50 31
Diabetics as percentage of total 2 09 - 2-4 2-97 3-3 2-8 1-53
P.M.'s.
Malignanttumoursaspercentageof 12-15 17 3 16-77 18-3 19-8 18-1
total P.M.'s.
Malignanttumoursaspercentageof 12-7 17-7 17-3 18-95 20-4 18-3
non-diabetics
Malignant tumours as percentage of 8-2 8-4 8-3 9 95 9 27 7-1 8-8
diabetics
Time of publication . 1940 1944 1952 1954 1955 1959
We shall consider as a particular case the last of these investigations which
does not differ essentially from the others in its results. On the basis of 22,971
P.M. records from the University Clinic of Halle a/S the percentage of malignant
cases resulted as 18, remarkably close to the figure for Bristol, 19-2. The percent-
age of coincidence cases of diabetes and malignant disease was for Halle 8-8 per
cent, again remarkably close to the figure for Bristol, 10'1 per cent. The signi-
ficance test shows that we may regard the basis of the two investigations as one
statistical population of P.M.'s in which the percentages of tumours, 18 and 19-2
differ by not more than could be accounted for by random sampling from that
one population. The same applies to the percentages of coincidence cases, 8-8
and 1041 per cent.
To counter the possible objection that the negative association between malig-
nant disease and diabetes is only apparent and due to the fact that the diabetic
does not live long enough to be attacked by malignant disease, we give below the
age distribution of the coincidence cases which shows the coincidence cases as
not being different in age distribution from the total of cancer cases.
The same is, by and large, true for the German coincidence cases. Both
malignancy and diabetes and also the coincidence cases, increase with age and
then decrease again. The peak of the age curve in Germany lies between 55 and
65 years for malignancy and for the diabetics between 61 and 70 years, and for
the coincidence cases between 71 and 80 years. This means that today diabetics
reach a sufficiently high age to be exposed to the risk of the malignant disease
like other parts of the population.
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TABLE IV.-Age, Sex and Sitefor the 19 Coincidence Ca8e8of Cancer and
Diabete8Mentioned in Table I
Site Sex Age
Breast F. 62
F. 60
M. 80
Gall bladder F. 47
Kidney M. 74
Larynx M. 83
Lung M. 57
F. 47
M. 46
M. 75
Pancreas M. 65
F. 51
M. 58
Rectum M. 73
M. 70
Stomach F. 74
F. 65
Leukaemia F. 73
Lymphocarcinoma M. 64
Although the difference between the Bristol percentages and those of Halle
of the same denomination are not statistically significant, yet one might be
somewhat uneasy about what looks like a slight systematic increase in the Bristol
percentages: 19-2 against 18 per cent for malignant cases, and 10-1 against 8-8
per cent for coincidence cases. However, the explanation may lie in the change
of diabetes incidence with time. As is well known, diabetes is, in general, on
the increase in both England and Germany and so is cancer of certain sites. In
spite of the agreement between the Bristol figures and those from Halle a/S
there is a difference in the sex distribution between the two samples. For Halle
the relation between M. and F. among the diabetics is 0-78 to 1 and that for the
coincidence cases 0-82 to 1. For the malignant tumours without diabetes the
relation is 1-33 to 1. The corresponding figures for Bristol are 0-48: 1, 1-38: 1
and 2-24: 1. The statistical influence ofthe striking difference in sex distribution
for tumours and diabetes upon the coincidence rate is discussed in Section 5.
Regarding the relation of the analysis of post mortem records to mortality
statistics of the whole population in England and Wales, the following figures
were obtained for 1950:
Deaths as percentage
of all deaths
Cancer (%)
M. 0-170 17
F. 0-172 17 approx.
Diabetes
M. 0-00468 0-5
F. 0-00989 1-0
Although the percentage of cancer cases among the P.M.'s is in fairly good agree-
ment with that in the totalpopulation-19 asagainst 17 per cent-the percentage
ofdiabetics among the P.M.'s, approximately 3 per cent, is ratherhigher than the
percentages in the total population, 0-5 for males and 1-0 per cent for females,453 CANCER AND DIABETES MELLITUS
which might conceivably have been responsible for a higher percentage of co-
incidence cases, but not for the actually observed lower percentage. However,
attention is drawn to the fact that the relation of diabetic M. and F. in the
population is almost precisely that for the diabetics among the P.M.'s. We have
61 M. : 128 F. = I : 2
and in the population, we have the diabetes percentage of all deaths
0-5 M. : 1-0 F. 1 :2.
Section 3
The stability of the corresponding percentages in different investigations is so
remarkable that it calls for comment from both the medical and statisticalangle.
It is often maintained that P.M.'s cannot be regarded as a random sample of the
mortality in a given country, since there is no definite rule as to which cases are
to be subjected to autopsy. It largely depends on the preference which the
consultants in question have in this respect, and this may be different at different
times according to which type of disease is specially in the foreground of medical
interest. This is then adduced as a reason for the doubtfulness ofcomparability
between mass results based on P.M.'s.
While it is readily admitted that the basis of true comparability of statistical
results is that they were obtained in the same manner, yet to overdo this and
restrict thepossibility ofcomparison in this way would be against the very nature
of statistics. Statistics is a method to be applied where the strict requirements
of laboratory experimentation cannot be obtained. In observation of masses
of events which is the very essence of statistics, it is just the impossibility of
following each individual case which makes statistical methods necessary. That
in spite of the lack of complete comparability between mass results there should
be a certain stability is the'very basis for the conception of medical statistics as
conceived by Dr. Farr.
Applying these considerations to P.M.'s, we must, on the basis of the present
investigation, arrive at the conclusion that in spite ofthe P.M.'s at differenthospi-
tals being carried out by different persons with different points of view, a suffi-
cientlv -areat number of these autopsies-provided only that there is no true, i.e.
intentional, bias oftheinvestigator-can beregarded as asample ofthepopulation
of P.M.'s. Rightly understood, a conclusion of this kind expresses in words
what must be the basis of any medical inference about a certain amount of pro-
tection from malignant diseases in diabetics. As a biological or pathological fact, it must apply to mankind in general, provided only that the living co-ii-
ditions, etc., are comparable.
However, in spite ofgiving, by and large, a fair picture of the relations of the
rates in the population for the two diseases in question, we cannot, in the strict
sense ofthe term, regard agiven mass ofP.M.'s as a raDdom sample ofthepopula-
tion mortality, but the stability of proportions we have noticed among the
different massesofP.M.'s justifies regarding these masses as representing a statisti-
cal population in its own right. What it loses by not being strictly a random
sample of population mortality it gains by the greater reliability of diagnosis
and by the completeness of the morbidity picture which it affords.
The difference between the distribution of deaths from certain causes in the
general population and in the population ofP.M.'s is readily admitted, but it does454 G. HERDAN
not matter for ourargument, since thepercentages which we compare, i.e. those of
malignant tumours and diabetes, are both from the same population of P.M.'s.
The difference from the general population influences therefore both percentages
in the same way.
It should also be noted that we are not concerned with the percentage of
diabetics among the P.M.'s, which may, and probably will, differ from that in the
general population, but only with the percentage of diabetics among tumours,
i.e. with the coincidence cases. Even if the number of diabetics were system-
atically too small compared with what it is in the general population, this need
have no influence upon the number of coincidences.
Section 4
According to the literature, the clinical experience did not always seem to
bear out the conclusion reached from a study of P.M.'s. Thus, Constam (1950),
who gives the percentage of the incidence of malignant tumours in non-diabetics
as 3-0 per cent and among diabetics as 5-1 per cent.
In order to check these findings I obtained from Bristol Royal Hospit'al,
Royal Infirmary Branch, the corresponding data for 7 years, 1953-59, which are
set out in Table V.
TABLE V.-Morbidity Due to Malignant Diseases and Diabetes in the
Bristol Royal Infirmary
3 Patients with joint
Malignant diseases occurrence of diabetes
registered 4 and malignant tumour
2 Total number r --A
I Total number percentage of ofpatients Percentage of
Year ofin-patients Number in-patients with diabetes Number diabetics
1953 8,587 463 5- 39 142 3 2-11
1954 9,150 409 4- 47 145 6 4-14
1955 9,592 405 4-22 169 5 2-92
1956 9,651 753 7-80 171 2 1-17
1957 9,446 578 6-12 202 8 3-96
1958 9,524 587 6-16 205 4 1.95
1959 8,755 488 5-57 195 7 3-58
Totals 64,705 3,683 5-69 1,229 35 2-84
The results are most interesting in so far as they seem fully to support the
conclusion obtained from our P.M. data. The incidence of malignant tumours
among diabetics is considerably less than among all in-patients, the ratio between
the two overall percentages, 2-84 and 5-69, being approximately 0-50 which is in
good agreement with the ratio of the corresponding percentages obtained from
our P.M. data, 10-1 and 19-2, which is 0-53. The percentage of tumours among
non-diabetics is 5-75.
On the basis of our data, be they from P.M.'s or from clinical experience, we
have therefore, no reason to doubt thesignificantly reduced incidence ofmalignant
tumours among diabetics.
Section 5
Inspection of Table 11 with regard to the sex distribution, reveals the remark-
able fact that the number of female diabetics is more than twice that of male455 CANCER AND DIABETES MELLITUS
diabetics. This, in connection with the smaller frequency of malignant diseases
in females (M. : F. = 1-64: 1), at once suggests that the negative association
between diabetes and malignant tumours may not be quite homogeneous as
regards the sexes. Using the following symbols
C7, Total ofmalignant tumour patients
T Total of P.M.'s
CD Malignant tumours among diabetics
D Number of diabetics
and the subscript . for male and t for female
we have for males
CmITm K CDm
D
and substituting our figures
0-207 K, x 0.180
0-207 Ki == 1-15 0-180
aiid for females
CflTt
= K CDI.
2 Dt
in figures 0-172 K2 X 0-063
K2 0-172/0-063
= 2-73
In words: for males the incidence of malignant tumours in the population of
autopsies is 1-15 times that amongdiabetics, whereas for females thecorresponding
figure is 2-73 ; orconversely, the occurrence ofmalignant tumours among diabetic
males is 87 per cent of that in the total autopsies population, whereas for females
it is only 37 per cent.
This means that if the difference in sex distribution is duly taken into account
we find that the observed overall negative association between the two diseases
is. by and large, true only for the female sex. For males, the incidence ofmalig-
nant diseases in the total of autopsies is not significantly different from that
among diabetic autopsies (1-15 times).
Section 6.
Common to both diseases is thepathologicalchange inglucose metabolism. In
diabetes thetransport ofglucosethrough the cell membrane is slowed up. Accord-
ing to Rockstroh and Schr6ter (1960), the application of insulin causes glucose to
pass at an increased rate through the membrane into the cell, where it is used
for the production of energy. On the other hand, in the cancer cell, fermentation
of glucose goes through the same enzymatic reaction as in glycolysis, and since
the latter is activated by the application ofinsulin, insulin will increase anexisting
tumour ; Rockstroh and Schr6ter give references for this view. Considering now
that the quantity ofglucose required for producing a given amount of energy by glycolysis is about 10 times that required for producing the same amount of
energy by means ofrespiration (oxidation), they argue that it would seem under-
standable why a diabetic in the critical age does not suffer from metabolic upsets which would be favourable for the development of malignant tumours. The
glucose is not allowed to accumulate in the cell but is used on a large scale for the456 G. HERDAN
production of the energy by glycolysis because the other pathway, respiration,
is much reduced in the tumour cell.
The pioneer work of Warburg on the energy-producing reactions of tumours
has led to a vast amount of research on the subject. As a result, it is now clear
that these reactions depend to alarge extent on the metabolism ofcarbohydrates,
and that the metabolic pathways ofneoplastic cells differ considerably from those
of normal cells. Tumour cells can carry out both aerobic and anerobic glycolysis
but the latter process isparticularlyenhanced and veryhigh rates may be manifest.
Whilst the shift of emphasis in the -alvcolitic and respiratory capacities of
neoplastic cells from that obtaining in normal cells is well recognized, its signi-
ficance has been apoint ofcontroversy for many years. Warburg (1956) considers
it to be an irreversible alteration resulting from a change in the mitochondrial
respiratory system. In his view, damage to the respiratory apparatus in mito-
chondria of normal cells is followed by a selective process favouring the survival
of cells capable of increased permeation as a means of compensation. Many
other investigators believe however that the process of carcinogenesis depends
basically on nuclear changes, and Kit and Griffin (1958) regardprimarydamage to
respiratory grana as being significant only if it results in nuclear alteration.
Thus in neoplasms there is a disturbance ofcarbohydrate metabolismlocalized
in the tumour cells, whereas in diabetes mellitus a generalized alteration ofthe
very same metabolic process exists. Henderson and LePage (1959) pointed out
that in the presence of an unusual carbohydrate metabolism certain compounds
may become essential to the growth of a tumour which would otherwise be
regarded as non-essential. In their review they summarize experimental obser-
vations which could be interpreted as evidence of an avidity of tumour cells for
glucose such that the normal tissues ofthe host are depleted ofsugar. From this
it seems that aneoplasm would becapable ofinfluencing theseverity of anexisting
diabetic state, so that the local disturbance of carbohydrate metabolism in the
tumour affects the general state of carbohydrate metabolism in diabetes.
This is the reverse of the possible influence of diabetes upon the incidence of
human tumours which emerges from the P.M. analysis given in Sections I and 2.
Acknowledgments are due to Mr. A. E. J. Turner, Group Medical Records
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